During the past decade, Huzhou Central Hospital conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 2 clinical trials were completed, i.e. on average, 10.5% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 2 clinical trials were completed. i.e. 11.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Huzhou Central Hospital" #1 sponsor was "Second Affiliated Hospital, School of Medicine, Zhejiang University" with 8 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Anji Pharma" with 1 trials sponsored, "BeiGene" with 1 trials sponsored and "China Academy of Chinese Medical Sciences" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Huzhou Central Hospital" #1 collaborator was "Huizhou Municipal Central Hospital" with 2 trials as a collaborator, "Affiliated Hospital of Nantong University" with 1 trials as a collaborator, "Anhui Provincial Hospital" with 1 trials as a collaborator, "Baotou Central Hospital" with 1 trials as a collaborator and "BeiGene, Ltd." with 1 trials as a collaborator. Other collaborators include 58 different institutions and companies that were collaborators in the rest 68 trials.

According to Clinical.Site data, the most researched conditions in "Huzhou Central Hospital" are "Airway Responsiveness" (2 trials), "Asthma" (2 trials), "Chest Syndrome" (2 trials), "Clinical Anxiety" (2 trials) and "Clinical Depression" (2 trials). Many other conditions were trialed in "Huzhou Central Hospital" in a lesser frequency.

Most popular intervention types in "Huzhou Central Hospital" are "Drug" (16 trials), "Device" (2 trials), "Biological" (1 trials), "Diagnostic Test" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Tirzepatide" (3 trials), "B7-H3 CAR-T" (1 trials), "Chiglitazar 32mg" (1 trials) and "Chiglitazar 48mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Huzhou Central Hospital" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Huzhou Central Hospital". 1 are not yet recruiting, 10 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Huzhou Central Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Huzhou Central Hospital, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 5 trials that are defined as “Not Applicable".